Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFA 0703 ATRA plus chemotherapy or azacitidine salvage and azacitidine maintenance in older AML
2006-005562-39Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) comparing ATRA plus chemotherapy induction, Azacitidine ± ATRA induction/salvage and Azacitidine maintenance (3 arms). Primary endpoint: Event-free survival. Started Jun 2008; status: active.
02
Drugs
tretinoinazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-005562-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005562-39.